Search This Blog

Friday, July 28, 2023

Okyo to Initiate Phase 2 Trial of OK-101 in Neuropathic Corneal Pain

 

  • OKYO plans a 40-patient OK-101 open-label clinical trial with Dr Pedram Hamrah, Tufts Medical Center, as Principal Investigator, a leading expert in treating patients with NCP

  • Second clinical indication for OK-101 which is currently in 240 patient phase 2 clinical trial to treat dry eye disease, with top-line data anticipated by end of 2023

  • NCP trial anticipated to start in Q4 2023

Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)